ANZ MedTech Market Entry: The Regulatory-first Approach That Actually Works

The ANZ grouping makes sense commercially; both markets share language, clinical culture, and distributor networks. Regulatorily, however, they operate under separate frameworks, with different classification systems, different submission processes, and different reimbursement mechanisms. A device approved under TGA does not automatically carry Medsafe clearance, and vice versa.

The practical consequence: your ANZ entry plan needs two regulatory tracks running in parallel, not a single submission with a copy-and-paste appendix for the second country.

The Importance of Preparation

Most MedTech companies entering ANZ from Europe or North America have an existing technical file. The question is not whether you have documentation, it is whether that documentation satisfies TGA's specific requirements for your device class and conformity assessment route.

TGA accepts conformity assessment evidence from recognised overseas bodies, but the mapping is not automatic. Common gaps include Australian-specific labelling requirements, post-market surveillance obligations aligned to TGA's Unique Device Identification (UDI) framework, and clinical evidence standards that differ from EU MDR clinical evaluation expectations.

Why is a gap analysis important? The work that you put into it during weeks one through to four will become the input that determines whether your 9-month plan is realistic or optimistic. Discovering a material gap at month 5 is how launches slip to the following financial year.

Distributor or Direct? The ANZ Decision

The Australian MedTech market is large enough to support a direct commercial presence for high-value or complex devices, but most first-entry companies use a distributor for speed and established hospital access. New Zealand is almost always distributor-led given the market size there.

The distributor vetting process should include confirmation that the distributor can act as, or has a relationship with, an ARTG sponsor. Many distributors in ANZ bundle distribution and sponsor functions but this simplifies structure and can create dependency on a single commercial partner. Separating the sponsor relationship from the distribution relationship gives more flexibility as the business scales.

Distributor commitments that lack volume targets are difficult to exit, so ensure that you negotiate performance milestones with clear timelines. In Australia, distributor exclusivity terms tend to run 2–3 years for initial agreements.

Which Variable Determines Commercial Scale?

ARTG listing is a market access threshold, not a revenue driver. In Australia, reimbursement through the MBS (Medicare Benefits Schedule) determines whether clinicians can use your device in a funded context. Private hospital use and self-pay pathways exist but represent a narrow slice of total addressable volume for most device categories.

The MSAC (Medical Services Advisory Committee) pathway applies to devices requiring a new MBS item number. The process is evidence-intensive and runs 12 to 24 months from submission to determination. For devices that fit under an existing MBS code, the pathway is faster but requires a clear mapping exercise with health economics support.

New Zealand reimbursement runs through PHARMAC, which covers both pharmaceuticals and some medical devices. PHARMAC operates a contestable funding model, and device applications compete against other health interventions on cost-effectiveness grounds. The evidentiary bar is high and the timeline is variable. In this case budget for 18 months from submission.

How do These Pieces Fit Together?

None of these workstreams sit in isolation. The technical file gap analysis informs your sponsor and distributor conversations, your distributor agreement shapes how quickly you can move once ARTG listing comes through, and your reimbursement pathway determines whether that listing translates into sustainable volume. Treat ANZ as two markets with one shared sequence, start with regulatory clarity, and the rest tends to fall into place on schedule.

If you're mapping this out for your own device, that's exactly where Arcadia can help.